Silver In Situ Hybridization (SISH) For Determination of HER2 Gene Status in Breast Carcinoma-Reference-Cited by-同舟云学术

Silver In Situ Hybridization (SISH) For Determination of HER2 Gene Status in Breast Carcinoma

Published:2010-06 Issue:6 Volume:34 Page:767-776
ISSN:0147-5185
Container-title:American Journal of Surgical Pathology
language:en
Short-container-title:

Author:

Papouchado Bettina G.,Myles Jonathan,Lloyd Ricardo V.,Stoler Mark,Oliveira Andre M.,Downs-Kelly Erinn,Morey Adrienne,Bilous Michael,Nagle Ray,Prescott Nichole,Wang Lin,Dragovich Lidija,McElhinny Abigail,Garcia Carole Ferrell,Ranger-Moore Jim,Free Heather,Powell William,Loftus Margaret,Pettay James,Gaire Fabien,Roberts Christopher,Dietel Manfred,Roche Patrick,Grogan Thomas,Tubbs Raymond

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pathology and Forensic Medicine,Surgery,Anatomy

Reference48 articles.

1. Agreement between chromogenic in situ hybridization (CISH) and FISH in the determination of HER2 status in breast cancer;Arnould;Br J Cancer,2003

2. Chromogenic in situ hybridization: a multicenter study comparing silver in situ hybridization with FISH;Bartlett;Am J Clin Pathol,2009

3. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of Paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts;Baselga;Cancer Res,1998

4. HER2/Neu: mechanisms of dimerization/oligomerization;Brennan;Oncogene,2000

5. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group;Budman;J Natl Cancer Inst,1998

Cited by 82 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Image analysis for bright-field HER2 in situ hybridization: validation for clinical use;Virchows Archiv;2024-08-07

2. Effect of HER2/CEP17 ratio on survival in metastatic HER2-positive gastric cancer, multicenter study;Clinical and Translational Oncology;2024-03-07

3. HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results;Breast Cancer Research;2023-12-14

4. Subtypes of high-grade breast ductal carcinoma in situ (DCIS): incidence and potential clinical impact;Breast Cancer Research and Treatment;2023-07-15

5. HER2 Gene Protein Assay: A Robust Tool for Evaluating HER2 Status and Intratumoral Heterogeneity in Endometrial Cancers;American Journal of Clinical Pathology;2023-03-01